Alex Karnal, co-founder and Chief Investment Officer of Braidwell, appeared on Bloomberg's The Pulse with Francine Lacqua to discuss the profound impact of artificial intelligence on the healthcare ecosystem. Karnal highlighted how AI is enabling solutions to healthcare problems that were previously unattainable due to limitations in problem-solving capabilities, time, and capital requirements. He emphasized that the integration of AI is leading to a system focused on earlier risk detection, accelerated discovery processes, and ultimately, a more patient-centric healthcare model built on trust, experience, and improved outcomes.
Karnal's insights align with broader trends indicating a significant shift in the pharmaceutical industry. Braidwell, an investment firm that achieved a 28% return last year in its hedge fund arm, is doubling down on AI-focused biopharmaceutical companies. This commitment is evident in a new "infrastructure moment" for AI and biotech, where pharma companies are moving beyond pilot programs to make substantial, multi-year commitments to AI models and systems, rather than just transactional deals or asset purchases. This includes partnerships like NOETIK's foundation model licensing deal with GSK, Chai Discovery's agreement with Eli Lilly to build proprietary models, and Boltz's collaboration with Pfizer for biomolecular models.
Braidwell's strategy involves not only investing in AI-enabled medicine companies but also developing platforms and tools for medicine makers. The firm, with approximately $3.1 billion in assets under management at the end of last December, has a diverse team including molecular biologists, AI engineers, and portfolio managers, aiming to blend traditional Wall Street investing with medical science and AI. They have backed early-stage AI-biology companies such as Lila Sciences, which uses AI to run thousands of parallel experiments, and Proxima, which employs AI to design new classes of medicines.
Karnal and co-founder Brian Kreiter initiated Braidwell during the COVID-19 pandemic, driven by a vision to build and support healthcare companies that leverage AI. They aim to use AI in their investment processes to identify unmet medical needs and, through Braidwell Labs, to combine AI and science to discover and develop those medicines. This approach reflects a shift towards pragmatism and impact, with the goal of transforming human health by creating systems that make drug discovery faster, smarter, and more reliable for patients.
This infrastructure-level commitment to AI in biotech signals a fundamental change in how discovery happens. Researchers are moving away from traditional methods that often return to the same biological targets for diseases like Alzheimer's or Parkinson's. Instead, AI is helping uncover new disease targets and accelerate the development of novel treatments, as seen in Roche's use of Recursion AI to identify new brain disease targets. The ultimate goal is to create new capabilities as the core machinery of drug development, making a tangible difference in patient lives.
